Psychedelic‐assisted therapy considered ‘breakthrough’ treatment for PTSD
Mental Health Weekly May 17, 2021 DOI: 10.1002/mhw.32791
Summary
AI-generated from the abstractPsychedelic-assisted therapy shows promise for patients with severe, chronic post-traumatic stress disorder, potentially advancing toward FDA approval, according to researchers from the Multidisciplinary Association for Psychedelic Studies. The therapy involves using psychedelic substances in assisted sessions to reduce symptoms and provide relief for chronic PTSD. This innovative approach in mental healthcare could represent a significant therapeutic advancement for psychiatric care, though specific results, sample sizes, or study designs are not detailed in the abstract.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Population | Patients with severe, chronic post-traumatic stress disorder |
| Topics | Psychedelic-assisted therapy |
| Keywords | PTSD Treatment Trauma therapy Chronic PTSD Relief Symptom reduction |
| Citations | 1 |
| Key finding | Psychedelic-assisted therapy shows promise for severe, chronic PTSD and could move toward FDA approval. |
Abstract
New research involving the use of psychedelic‐assisted therapy is showing promise and significant implications for patients with severe, chronic post‐traumatic stress disorder (PTSD) and could potentially move the needle further toward Food and Drug Administration (FDA) approval, say researchers from the Multidisciplinary Association for Psychedelic Studies (MAPS).